Name: AMYLYX PHARMACEUTICALS INC (AMLX) Stock
Brand: AMYLYX PHARMACEUTICALS INC
Rating: 6 (3 reviews)

AMLX Latest News, Press Relases and Analysis

All

Press Releases

10 hours ago - By: Chartmill

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028

8 hours ago - By: Grabar Law Office - Mentions: AVTR HUM MSS

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf

12 hours ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

13 hours ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

3 days ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

7 days ago - By: Grabar Law Office - Mentions: FIVE HUM TMCI

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf

7 days ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

10 days ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

13 days ago - By: Zacks Investment Research

What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?

15 days ago - By: Grabar Law Office - Mentions: BAX HUM FIVE

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf

15 days ago - By: Kuehn Law, PLLC

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

18 days ago - By: Grabar Law Office - Mentions: BAX FIVE HUM

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf

20 days ago - By: Grabar Law Office - Mentions: HUM FIVE HTZ

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

21 days ago - By: Bragar Eagel & Squire

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

23 days ago - By: Grabar Law Office - Mentions: HUM FIVE TMCI

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

24 days ago - By: Grabar Law Office - Mentions: FIVE HUM TMCI

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

a month ago - By: Grabar Law Office - Mentions: HUM FIVE VSTS

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

a month ago - By: Grabar Law Office - Mentions: VSTS HUM UNCY

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

a month ago - By: Kuehn Law, PLLC

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

2 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

2 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

2 months ago - By: Stocktwits - Mentions: IWMW VTWG BAC

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

2 months ago - By: Stocktwits

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder

2 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

2 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: The Motley Fool

Amylyx (AMLX) Q2 Net Loss Narrows 43%

3 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

3 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

4 months ago - By: Yahoo Finance

Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion

4 months ago - By: Bragar Eagel & Squire

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

4 months ago - By: Stocktwits - Mentions: GS

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial

4 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

4 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

4 months ago - By: Bragar Eagel & Squire

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

4 months ago - By: The Motley Fool

AMYLYX PHARMACEUTICALS INC (AMLX) Stock News

AMLX Latest News, Press Relases and Analysis

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Earnings Scheduled For November 6, 2025

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx (AMLX) Q2 Net Loss Narrows 43%

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Earnings Scheduled For August 7, 2025

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Why Shares in Amylyx Pharmaceuticals Soared This Week